The PennZone

  • Home
  • Business
  • Real Estate
  • Technology
  • Construction
  • Travel
  • Health
  • Non-profit
  • Legal

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Kilmaine Saints to Anchor St. Patrick's Day Weekend with Live Album Recording at XL Live
  • Ice Melts. Infrastructure Fails. What Happens to Clean Water?
  • Revolutionary Data Solution Transforms Health Insurance Underwriting Accuracy
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • Caraline Skincare's Gentle Glow Cleansing Oil Named Finalist for Best Face Cleanser at the 2026 CertClean Clean Beauty Awards​
  • Workplace safety ideas from the front lines to highlight Applied Ergonomics Conference in Arlington, Texas
  • ThoroughCare Appoints New Chief Executive Officer & Chief Growth Officer to Accelerate Expansion
  • OpenSSL Corporation Advisory Committees' Elections 2026: Results Announcement
  • Zarova Vodka Expands Its Ultra-Premium Spirits Portfolio Through Strategic Acquisitions

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Capsadyn® Launches on Amazon, Offering Non-Burning Capsaicin Pain Relief
  • Pita Chip Celebrates One Year at The Concourse at Comcast Center with Free Entrees for the Community
  • When Representation No Longer Reflects the District — Why I'm Voting for Pete Verbica
  • How Direct Home Buyers Are Simplifying the Selling Process for Philadelphia Homeowners
  • Off The Hook YS (NY SE: OTH) Executes Transformational Apex Acquisition, Creating Vertically Integrated Marine Powerhouse with $60M Inventory Capacity
  • Tri-State Area Entrepreneur Launches K-Chris: A Premium Digital Destination for Luxury Fragrances
  • Why One American Manufacturer Builds BBQ Smokers to Aerospace Standards
  • Diversified Roofing Solutions Strengthens Industry Leadership With Expanded Roofing Services Across South Florida
  • ZRCalc™ Cinema Card Calculator Now Available for Nikon ZR Shooters
  • Revolutionary Data Solution Transforms Health Insurance Underwriting Accuracy
  • $36 Million LOI to Acquire High Value Assets from Vivakor Inc in Oklahoma's STACK Play — Building Cash Flow and Scalable Power Infrastructure; $OLOX
  • Kobie Wins for AI Innovations in the 2026 Stevie® Awards for Sales & Customer Service
  • Author Jeff Bogle to Host Street Cats Mediterranean Cruise Featuring Cat Behaviorist Molly DeVoss
  • Berman | Sobin | Gross LLP Celebrates 35 Years of Advocating for Maryland's Injured Workers and Families
  • Art of Whiskey Hosts 3rd Annual San Francisco Tasting Experience During Super Bowl Week
  • Kilmaine Saints to Anchor St. Patrick's Day Weekend with Live Album Recording at XL Live
  • PADT Earns Prestigious 2025 Americas Customer Loyalty Award from Ansys, Part of Synopsys
  • Florida Keys Visitors Can Save 15 Percent With KeysCaribbean's Advanced Booking Discount
  • Sleep Basil Unveils Revamped Natural Latex Mattress Collection Page for Cooler, Cleaner, Better-Aligned Sleep
  • Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs

Popular on PennZone

  • Michael Judkins Releases New Poetry Book, Deeper Than You Think
  • Still Using Ice? FrostSkin Reinvents Hydration
  • Accountants Near Me Cheyenne Opens U.S. Directory for Accountants, Bookkeepers and Tax Services
  • OneVizion Announces Next Phase of Growth as Brad Kitchens Joins Board of Directors
  • Boston Industrial Solutions' Natron® 512N Series UV LED Ink Earns CPSIA Certification
  • Precision Adult Care Expands 24/7 Adult In-Home Care Services to Meet Growing Demand in the Coachella Valley
  • 2025 Top Lawyers - ELA Awards by Expert Law Attorneys
  • Cold. Clean. Anywhere. Meet FrostSkin
  • Jim Breuer is Coming to The Eichelberger Performing Arts Center This May
  • The Ms. Corporate America Maryland Competition Returns for an Unforgettable Evening of Leadership, Excellence, and Empowerment

Similar on PennZone

  • Capsadyn® Launches on Amazon, Offering Non-Burning Capsaicin Pain Relief
  • FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
  • Parkway Prosthodontics Achieves Breakthrough Full-Arch Reconstruction Case
  • Postmortem Pathology Expands to Phoenix: Bringing Families Answers During Their Most Difficult Moments
  • EPP Pricing Platform announces leadership transition to support long-term growth and continuity
  • Stipenda Appoints David Epstein as Chief Operating Officer
  • Metavalis Launches Massive Community Coat Drive in Branson to Support Local Residents
  • Crossroads4Hope Welcomes New Trustees to Board of Directors as Organization Enters 25th Year of Caring
  • SNS Research Launches SNS Market Intelligence Platform for visual market intelligence for pharma
  • High-Impact Mental Health Platform Approaching a Defining Regulatory Moment: Eclipsing 70,000 Patients on Real World Use of Ketamine: N ASDAQ: NRXP
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us